Bruno Giannetti, COO of Pharming
, said: "The approval from the EMA to manufacture Ruconest at the Sanofi Aramon (France) site is an important development for Pharming
as it will allow us to scale up manufacturing of Ruconest ahead of future market demand, particularly as we progress towards US approval of Ruconest with our partner, Santarus.
is developing innovative protein therapeutics for unmet medical needs.
All forward-looking statements are qualified in their entirety by this cautionary statement and neither Santarus nor Pharming
undertakes any obligation to revise or update this news release to reflect events or circumstances after the date hereof.
In 1998, Pharming
formed a joint venture with Genzyme for the development and commercialization of transgenic human alpha-Glucosidase for Pompe's disease.
Based on prior discussions with the FDA, Pharming
is planning to initiate an additional randomized placebo-controlled, clinical study with RHUCIN in approximately 50 patients to provide additional data in support of the 50 U/kg dose.
will have the option to draw down from the working capital facility in tranches in exchange for its ordinary shares plus retain control of the timing and amount of any funds draw down.
also said it had presented to the shareholders alternatives to deal with its negative equity situation.
Record numbers of banks are joining the growing ranks of businesses displaying the Catbird[TM] Pharming
Shield[TM] seal on websites to reassure customers that the site is safe and open for business.
will redeem the bond on a month by month basis such that the bond will be redeemed in full on 15 July 2012.
also said it issued to the bondholders a total of 38.
attacks are a growing crime that is invisible to victims, but easy to protect against with the Catbird Anti-Pharming
23 December 2011 - Dutch biotech Pharming
Group NV (AMS:PHARM) said today it had agreed to place with certain institutional investors EUR8.